Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations.

ABSTRACT:

Introduction

Myeloid-derived cells, particularly immature populations and tumor-associated macrophages, play a pivotal role in establishing immune tolerance and suppressing antitumor responses, thereby promoting cancer progression. Macrophage-derived lymphatic endothelial cell progenitors (M-LECP) are a population of VEGFR3/FLT4/CD310^/bone marrow-derived myeloid precursors that contribute to tumor lymphangiogenesis, metastases, and resistance to chemotherapy through activation of TLR receptors. In this context, we investigated the effects of fruquintinib, a selective oral VEGFR3/FLT4/CD310 inhibitor with high affinity for VEGFR3/FLT4/CD310, on tumor growth and size on colorectal (MC38, CT26) and breast (4T1, E0771) tumors. We next focused on its capacity to reshape the m

SUBMITTER: Suarez L 

PROVIDER: S-EPMC12738944 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature